Jul. 20 at 8:49 PM
$XLO reason for all the delays in data and IND’s : When a biotech company enters advanced, late-stage partnership or buyout discussions, they enter strict confidentiality agreements. If they have spectacular data, they cannot just release a random press release to the public while in deep negotiations.
Doing so would drastically alter the stock price and potentially breach the data-sharing exclusivity clauses with the negotiating partner. Often, the partner will explicitly require the biotech to hold off on publicizing new data sets until a deal is finalized so that the deal can be announced together as a massive package.
